PT  - JOURNAL ARTICLE
AU  - Yaseen M Arabi
AU  - Hasan M. Al-Dorzi
AU  - Musharaf Sadat
AU  - Dina Muharib
AU  - Haifa Algethamy
AU  - Fahad Al-Hameed
AU  - Ahmed Mady
AU  - Adnan AlGhamdi
AU  - Ghaleb. A. Al Mekhlafi
AU  - Abdulrahman A Al-Fares
AU  - Ayman Kharaba
AU  - Ali Al Bshabshe
AU  - Khalid Maghrabi
AU  - Khalid Al Ghamdi
AU  - Ghulam Rasool
AU  - Jamal Chalabi
AU  - Haifaa Ibrahim AlHumedi
AU  - Maram Hasan Sakkijha
AU  - Norah Khalid Alamrey
AU  - Rabeah Hamad Alhutail
AU  - Kaouthar Sifaoui
AU  - Mohammed Almaani
AU  - Rakan Alqahtani
AU  - Ahmad S Qureshi
AU  - Mohammed Moneer Hejazi
AU  - Hatim Arishi
AU  - Samah AlQahtani
AU  - Amro Mohamed Ghazi
AU  - Saleh T Baaziz
AU  - Abeer Othman Azhar
AU  - Sara Fahad Alabbas
AU  - Mohammed AlAqeely
AU  - Ohoud AlOrabi
AU  - Alia Al-Mutawa
AU  - Maha AlOtaibi
AU  - Omar Aldibaasi
AU  - Jesna Jose
AU  - Joel Starkopf
AU  - Jean-Charles Preiser
AU  - Anders Perner
AU  - Abdulaziz Al-Dawood
AU  - the Saudi Critical Care Trials Group
TI  - Replacing Protein via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients: A Multicenter Randomized Controlled Trial: The REPLENISH Trial Protocol
AID  - 10.1101/2022.11.10.22282161
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.11.10.22282161
4099  - http://medrxiv.org/content/early/2022/11/11/2022.11.10.22282161.short
4100  - http://medrxiv.org/content/early/2022/11/11/2022.11.10.22282161.full
AB  - Background Protein intake is recommended in critically ill patients to mitigate the negative effects of critical illness-induced catabolism and muscle wasting. However, the optimal dose of enteral protein remains unknown. We hypothesize that supplemental enteral protein (1.2 g/kg/day) added to standard enteral nutrition formula to achieve high amount of enteral protein (range 2-2.4 g/kg/day) given from ICU day 5 until ICU discharge or ICU day 90 as compared to no supplemental enteral protein to achieve moderate amount enteral protein (0.8-1.2 g/kg/day) would reduce all-cause 90-day mortality in adult critically ill mechanically ventilated patients.Methods The REPLENISH (Replacing Protein Via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients) trial is an open-label, multicenter randomized clinical trial. Patients will be randomized to the Supplemental protein group or the Control group. Patients in both groups will receive the primary enteral formula as per the treating team, which includes a maximum protein 1.2 g/kg/day. The Supplemental protein group will receive, in addition, supplemental protein at 1.2 g/kg/day starting the fifth ICU day. The Control group will receive the primary formula without supplemental protein. The primary outcome is 90-day all-cause mortality. Other outcomes include functional and quality of life assessments at 90 days. The trial will enroll 2502 patients.Discussion The study has been initiated in September 2021. Interim analysis is planned at one third and two thirds of the target sample size. The study is expected to be completed by the end of 2024Trial Registration ClinicalTrials.gov Identifier: NCT04475666. Registered on July 17, 2020 https://clinicaltrials.gov/ct2/show/NCT04475666Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04475666Funding StatementThe study is sponsored by King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that will support the findings of this study are available from the corresponding author upon reasonable request as per the regulations of King Abdullah International Medical Research Center (KAIMRC)APACHEAcute Physiology and Chronic Health EvaluationDSMBData Safety Monitoring BoardESPENEuropean Society for Clinical Nutrition and MetabolismICUIntensive Care UnitKDIGOKidney Disease: Improving Global OutcomesPNParenteral NutritionRCTRandomized Controlled TrialSOFASequential Organ Failure Assessment